<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The adenylate kinase (AK) enzyme activity in plasma and CSF of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarctions</z:e> was examined </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:mpath ids='MPATH_458'>normal</z:mpath> values of enzyme activity in plasma reached from 1.7-5.6 U/l, and in CSF from 0.23-0.71 U/l </plain></SENT>
<SENT sid="2" pm="."><plain>According to this present classification a significant CSF increase in AK activity was found with semi-severe and severe <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarctions</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>With the CCT an increased enzyme activity was shown with infarction in or close to the cortex </plain></SENT>
<SENT sid="4" pm="."><plain>In no case was an alteration of AK activity in the serum sample </plain></SENT>
<SENT sid="5" pm="."><plain>CSF samples showing blood contamination or pleocytosis led to false pathological results with examination of AK activity </plain></SENT>
</text></document>